A recent study in Nature Medicine reveals two blood biomarkers that could predict cognitive deficits six and 12 months post-COVID-19 diagnosis, including COVID brain fog. These findings, drawn from data from over 1,800 hospitalized COVID-19 patients, were verified in an independent dataset. They offer biological insights into the factors possibly underlying long-term cognitive impairment from COVID-19.
Cognitive deficits following COVID-19, often described as “COVID brain fog,” can severely impact daily life. Diagnosis combines objective (clinician-assessed) and subjective (patient-reported) elements. Yet, the development of these post-COVID-19 cognitive deficits remains a mystery.
Maxime Taquet and their team conducted a comprehensive analysis using data from 1,837 COVID-19 patients hospitalized in the U.K. from January 29, 2020, to November 20, 2021. Blood samples were collected during admission. Both clinician-assessed and patient-reported cognition measurements were collected at six and 12 months post-admission.
Employing advanced statistical techniques, the researchers pinpointed two blood biomarker profiles strongly linked to post-acute COVID-19 cognitive impairments. The first profile revealed elevated fibrinogen levels, a blood coagulation-related protein, showing significant correlations with both objective and subjective cognitive deficits. Meanwhile, the second profile associated heightened d-dimer levels, another blood coagulation protein, with subjective cognitive deficits, including COVID brain fog, and also with symptoms like fatigue and shortness of breath.
These results were substantially duplicated in an independent investigation involving the medical records of 17,911 U.S. patients. This included a comparison between post-pandemic and pre-pandemic groups, highlighting the distinctiveness of d-dimer concerning COVID-19, as proposed by the authors.
The authors posit that their discoveries may pave the way for the creation of predictive models for post-COVID-19 cognitive impairments, aiding in prognosis and treatment planning. Nevertheless, they underscore the necessity for additional research involving diverse cohorts to validate these findings.
more recommended stories
-
DNA Damage Triggers New Cell Death Pathway
Tumor cells are killed by chemotherapy,.
-
Comorbidities Worsen Sleep Quality in Multiple Sclerosis
Comorbidities in multiple sclerosis (MS) are.
-
Latitude and Skin Type-Based Vitamin D Guidelines
In a recent study published in.
-
AOMs Reduce CVD Risk in Obese Medicare Patients
Obesity is a leading cause of.
-
Dopamine Linked to Brain Development in ASD
Summary: A recent study links autism.
-
Microplastics in Human Blood: Cardiovascular Risk
An investigation disclosed in the esteemed.
-
Gene Therapy Offers Hope for X-linked Sideroblastic Anemia
ALAS2 gene mutations that are essential.
-
Mini Brains: Advancing Alzheimer’s Research
In summary, scientists created microscopic “mini-brains”.
-
Inflammatory Bowel Disease Linked to Parkinson’s Disease
Both inflammatory bowel disease (IBD) and.
-
NMSC Skin Cancer: Rhenium-188 as Surgery Alternative
According to a recent study published.
Leave a Comment